DCTH
Delcath Systems, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$16.45
−0.18%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+53.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| May 14, 2026 | CZEREPAK ELIZABETH · director | A-Award | 22,500 | $12 |
| May 14, 2026 | Sylvester John Richard · director | A-Award | 22,500 | $12 |
| May 14, 2026 | SALAMON STEVEN A J · director | A-Award | 22,500 | $12 |
| May 14, 2026 | Martell Bridget A · director | A-Award | 22,500 | $12 |
| May 14, 2026 | Aharon Gil · director | A-Award | 22,500 | $12 |
| Mar 6, 2026 | Pennell Sandra · officer: Chief Financial Officer | Purchase | 5,533 | $9.04 |
| Feb 18, 2026 | MICHEL GERARD J · director, officer: CHIEF EXECUTIVE OFFICER | A-Award | 97,500 | $0.00 |
| Feb 18, 2026 | Vukovic Vojo · officer: CHIEF MEDICAL OFFICER | A-Award | 56,500 | $9.40 |
| Feb 18, 2026 | Pennell Sandra · officer: Chief Financial Officer | A-Award | 28,250 | $0.00 |
| Feb 18, 2026 | Hoffman David L. · officer: GEN'L COUNSEL, CCO & SECY | A-Award | 28,250 | $0.00 |
| Feb 18, 2026 | Muir Kevin · officer: GM INTERVENTIONAL ONCOLOGY | A-Award | 28,250 | $0.00 |
| Feb 18, 2026 | Pennell Sandra · officer: Chief Financial Officer | A-Award | 56,500 | $9.40 |
| Feb 18, 2026 | Rook Martha S. · officer: CHIEF OPERATING OFFICER | A-Award | 56,500 | $9.40 |
| Feb 18, 2026 | Rook Martha S. · officer: CHIEF OPERATING OFFICER | A-Award | 28,250 | $0.00 |
| Feb 18, 2026 | Vukovic Vojo · officer: CHIEF MEDICAL OFFICER | A-Award | 28,250 | $0.00 |
| Feb 18, 2026 | Muir Kevin · officer: GM INTERVENTIONAL ONCOLOGY | A-Award | 56,500 | $9.40 |
| Feb 18, 2026 | Hoffman David L. · officer: GEN'L COUNSEL, CCO & SECY | A-Award | 56,500 | $9.40 |
| Feb 18, 2026 | MICHEL GERARD J · director, officer: CHIEF EXECUTIVE OFFICER | A-Award | 195,000 | $9.40 |
| Nov 25, 2025 | Sylvester John Richard · director | Purchase | 4,386 | $8.89 |
| Nov 13, 2025 | MICHEL GERARD J · director, officer: CHIEF EXECUTIVE OFFICER | Purchase | 11,500 | $8.53 |
| Jun 13, 2025 | Vukovic Vojo · officer: CHIEF MEDICAL OFFICER | M-Exempt | 42,000 | $4.78 |
| May 19, 2025 | Sylvester John Richard · director | A-Award | 22,500 | $16 |
| May 19, 2025 | SALAMON STEVEN A J · director | A-Award | 22,500 | $16 |
| May 19, 2025 | Aharon Gil · director | A-Award | 22,500 | $16 |
| May 19, 2025 | CZEREPAK ELIZABETH · director | A-Award | 22,500 | $16 |
| May 19, 2025 | Martell Bridget A · director | A-Award | 22,500 | $16 |
| Feb 7, 2025 | Hoffman David L. · officer: GEN'L COUNSEL, CCO & SECY | A-Award | 113,000 | $16 |
| Feb 7, 2025 | MICHEL GERARD J · director, officer: CHIEF EXECUTIVE OFFICER | A-Award | 390,000 | $16 |
| Feb 7, 2025 | Vukovic Vojo · officer: CHIEF MEDICAL OFFICER | A-Award | 113,000 | $16 |
| Feb 7, 2025 | Rook Martha S. · officer: CHIEF OPERATING OFFICER | A-Award | 113,000 | $16 |
Institutional positioning
13F filings over the trailing two quarters
New 47Increased 86Reduced 65Sold out 19
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ROSALIND ADVISORS, INC. | Unchanged | 3,300,389 | May 14, 2026 |
| Rosalind Advisors, Inc. | Unchanged | 3,300,389 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 2,706,802 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 1,784,466 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,329,288 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 1,221,247 | Aug 13, 2026 |
| PROPEL BIO MANAGEMENT, LLC | Increased | 979,698 | May 14, 2026 |
| Propel Bio Management, LLC | Reduced | 871,460 | Aug 13, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 733,115 | Aug 12, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 692,031 | May 15, 2026 |
| STATE STREET CORP | Increased | 679,280 | Aug 7, 2026 |
| STATE STREET CORP | Increased | 664,428 | May 15, 2026 |
| PRIVATE WEALTH ADVISORS, LLC | Increased | 591,524 | May 13, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 588,055 | May 15, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 587,678 | Mar 25, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing May 14, 2026